Blocking CXCR6 expression with shRNA has demonstrated reduced tumor growth, cytokine secretion, invasiveness, and metastasis in xenograft studies, validating CXCR6, as a therapeutic target in HCC [3]. The gene discussed is CXCR6; the disease is neoplasm.